|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2007-7-26
|
|
pubmed:abstractText |
In the absence of major contraindications, treatment guidelines recommend that, following a major traumatic event, all patients receive low molecular weight heparin (e.g. enoxaparin) as thromboprophylaxis for the prevention of deep vein thrombosis (DVT).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1198-581X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e215-26
|
|
pubmed:meshHeading |
pubmed-meshheading:17652767-Adult,
pubmed-meshheading:17652767-Cost-Benefit Analysis,
pubmed-meshheading:17652767-Decision Trees,
pubmed-meshheading:17652767-Enoxaparin,
pubmed-meshheading:17652767-Female,
pubmed-meshheading:17652767-Heparin, Low-Molecular-Weight,
pubmed-meshheading:17652767-Humans,
pubmed-meshheading:17652767-Male,
pubmed-meshheading:17652767-Models, Statistical,
pubmed-meshheading:17652767-Venous Thrombosis,
pubmed-meshheading:17652767-Wounds and Injuries
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
|
|
pubmed:affiliation |
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada. llynd@interchange.ubc.ca <llynd@interchange.ubc.ca>
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
